Articles About NASDAQ:AMGN
January 31, 2014
Amgen's cholesterol-fighting drug evolocumab has met its goal in its fifth late-stage clinical trial, putting the company well ahead of competitors.
January 27, 2014
Amgen has a 62 percent positive surprise history, having topped the whisper in 32 of the 52 earnings reports for which we have data.